Hims & Hers
Health and wellness, personalized
Major national telehealth provider offering both injectable and oral GLP-1 weight loss medications with direct Novo Nordisk partnership for Wegovy access.
Medications Available
Pros
- Both injectable and oral options available
- Direct partnership with Novo Nordisk
- Quick customer service response
- Competitive pricing for compounded medications
- Nationwide availability
Cons
- No insurance accepted
- Best pricing requires upfront payment for multi-month plans
- Limited coaching compared to some competitors
Compare Hims & Hers With
See how Hims & Hers stacks up against other providers
How Hims & Hers Ranks
See where Hims & Hers places in our expert rankings
About Hims & Hers
Hims & Hers is a major national telehealth provider founded in 2017 in San Francisco. They offer both injectable and oral GLP-1 weight loss medications and have a direct partnership with Novo Nordisk for Wegovy access. The platform serves both men (Hims) and women (Hers) with personalized health and wellness solutions.
How It Works
- Online Consultation - Complete an async health assessment
- Provider Review - Licensed clinicians evaluate your eligibility
- Choose Your Plan - Select from oral or injectable options
- Home Delivery - Medication ships with free shipping and cold chain handling
Pricing (February 2026)
| Plan | Price | Medication |
|---|---|---|
| Oral Weight Loss Kit | $69/mo | Oral medications (10-month plan upfront) |
| GLP-1 Injectable - 6 Month | $199/mo | Compounded Semaglutide (paid upfront) |
| GLP-1 Injectable Monthly | $299/mo | Compounded Semaglutide (month-to-month) |
| Tirzepatide - 6 Month | $349/mo | Compounded Tirzepatide (paid upfront) |
| Tirzepatide Monthly | $449/mo | Compounded Tirzepatide (month-to-month) |
| Generic Liraglutide | $299/mo | FDA-approved generic GLP-1 |
Free consultations and shipping on all plans. HSA/FSA eligible.
Recent News (February 2026)
- Novo Nordisk Negotiations: Hims & Hers was initially left off Novo Nordisk’s list of eight telehealth partners for the new Wegovy pill, though active negotiations are ongoing
- UK Expansion: Launched Weight Loss Program in UK in December 2025
- Canadian Acquisition: Acquired Livewell (Canadian digital health platform) for expansion into Canada
- Technology Investment: Acquiring YourBio Health (capillary blood sampling technology)
- 2026 Revenue Target: $725 million in GLP-1 revenue projected for 2026
- Longevity Launch: Planning longevity specialty launch in 2026 featuring peptides, coenzymes, and GLP/GIP treatments
Who Is This Best For?
- Patients who prefer oral medications over injections
- Those looking for competitive compounded GLP-1 pricing
- People who want quick customer service response
- Patients seeking nationwide availability
The Bottom Line
Hims & Hers offers flexible GLP-1 options with both oral and injectable formulations at competitive prices. Their Novo Nordisk partnership provides access to brand-name Wegovy, while compounded options offer affordability.
Last updated: February 2026
Last verified: February 2026
Ready to try Hims & Hers?
Compare with other providers or visit their website to get started.